AgomAb Therapeutics NV American Depositary Shares (AGMB)
NASDAQ (NMS) NASDAQ (NMS) Primary 
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis
Agomab Therapeutics targets fibrotic strictures in Crohn's disease, aiming to create a new treatment category rather than compete with existing therapies. AGMB's ontunisertib showed promising endoscopic results and safety in Phase 2a, with further validation needed in larger, controlled trials. Strong funding runway through 2029 and disciplined R&D execution support AGMB's ability to advance clinical programs without immediate dilution risk.
AgomAb Therapeutics: High Risk, High Reward Stock
AgomAb Therapeutics offers high-risk, high-reward potential driven by two late-stage immunology drugs targeting large addressable markets. AGMB-129 (Crohn's disease) and AGMB-447 (IPF) have Fast Track and Orphan Drug designations, indicating significant unmet need and regulatory advantages. Strong backing from major pharma players and a high institutional ownership position, AGOM is a potential acquisition target upon successful trial outcomes.
